Literature DB >> 11113646

Cause of high variability in drug dissolution testing and its impact on setting tolerances.

S A Qureshi1, J Shabnam.   

Abstract

Considering a variable mixing/stirring and flow pattern in a drug dissolution vessel as a likely source of high variability in results, experiments were conducted using USP paddle apparatus by placing (aligned to the walls) a metal strip (1.7 mm thickx6.4 mm wide) in a dissolution vessel. The metal strip forces the undisintegrated tablet to settle about 3 mm away from the centre, facilitates spread of disintegrated material and diminishes the cone formation at the bottom of the vessel. To assess the impact of this altered environment in the vessel, but still maintaining the vessel dimensions within required specifications, drug release characteristics were evaluated for products having different formulation/manufacturing attributes. Tests were conducted with calibrator tablets (USP prednisone and salicylic acid tablets and FDA proposed NCDA No. 2 prednisone tablets) and two commercially available products (250 mg amoxicillin capsules and 5 mg glibenclamide tablets). Except for the glibenclamide tablet product, all products gave significantly (P<0.01) higher dissolution results with vessels containing metal strip than without. The extent of increased dissolution with the metal strip varied from product to product i.e. USP prednisone tablet was the smallest (14.4%) and NCDA No. 2 was the largest (88.4%). Based on the results obtained from this study, it is concluded that employing the current apparatuses, in many cases products will provide lower than anticipated results which may not be reflective of the product drug release characteristics. Test-to-test variability, within or between laboratories, can also be very high depending on the settling position of the product once dropped in the vessel and/or due to slight aberration in the walls of the vessel by altering the extent of spread of disintegrated material at the bottom of the vessel. Thus, dissolution testing will require wider tolerances to be useful for comparison of batch-to-batch or interlaboratory results.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11113646     DOI: 10.1016/s0928-0987(00)00174-3

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Simulating the hydrodynamic conditions in the United States Pharmacopeia paddle dissolution apparatus.

Authors:  Leonard G McCarthy; Carolin Kosiol; Anne Marie Healy; Geoff Bradley; James C Sexton; Owen I Corrigan
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

2.  Shear-induced variability in the United States Pharmacopeia Apparatus 2: modifications to the existing system.

Authors:  Jennifer L Baxter; Joseph Kukura; Fernando J Muzzio
Journal:  AAPS J       Date:  2006-01-03       Impact factor: 4.009

3.  Velocity distribution and shear rate variability resulting from changes in the impeller location in the USP dissolution testing apparatus II.

Authors:  Ge Bai; Piero M Armenante
Journal:  Pharm Res       Date:  2007-11-27       Impact factor: 4.200

Review 4.  The science of USP 1 and 2 dissolution: present challenges and future relevance.

Authors:  Vivian Gray; Gregg Kelly; Min Xia; Chris Butler; Saji Thomas; Stephen Mayock
Journal:  Pharm Res       Date:  2009-01-23       Impact factor: 4.200

5.  Transfer of drug dissolution testing by statistical approaches: Case study.

Authors:  Mohammed Amood Al-Kamarany; Miloud El Karbane; Khadija Ridouan; Fars K Alanazi; Philippe Hubert; Yahia Cherrah; Abdelaziz Bouklouze
Journal:  Saudi Pharm J       Date:  2011-09-16       Impact factor: 4.330

6.  The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets: quality attributes and experimental variables contributing to dissolution variance.

Authors:  Gang Deng; Alyssa J Ashley; William E Brown; Joseph W Eaton; Walter W Hauck; Loice C Kikwai; Mark R Liddell; Ronald G Manning; Jimmy M Munoz; Pallavi Nithyanandan; Maria J Glasgow; Erika Stippler; Samir Z Wahab; Roger L Williams
Journal:  Pharm Res       Date:  2008-01-03       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.